A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers
Latest Information Update: 14 May 2020
At a glance
- Drugs R 21 (Primary) ; Matrix M
- Indications Falciparum malaria
- Focus Adverse reactions
- 11 May 2020 According to a Novavax media release, top-line data from the trial is expected in the second quarter of 2020.
- 04 Jul 2018 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.